Health Care [ 10/12 ] | Health Care Equipment & Supplies [ 67/73 ]
NASDAQ | Common Stock
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States.
The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement.
The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body.
Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.41 Decreased by -95.24% | -0.51 Increased by +18.81% |
| Mar 24, 25 | -0.18 Decreased by -500.00% | -0.12 Decreased by -56.52% |
| Nov 12, 24 | -0.34 Decreased by -161.54% | -0.62 Increased by +45.16% |
| Aug 12, 24 | -0.41 Decreased by -86.36% | -0.21 Decreased by -95.24% |
| May 13, 24 | -0.21 Decreased by -50.00% | -0.07 Decreased by -200.00% |
| Mar 25, 24 | -0.03 Increased by +92.11% | -0.13 Increased by +76.92% |
| Nov 13, 23 | -0.13 Increased by +27.78% | -0.04 Decreased by -225.00% |
| Aug 14, 23 | -0.22 Increased by +47.62% | -0.13 Decreased by -69.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 23.43 M Increased by +26.42% | -3.53 M Decreased by -99.93% | Decreased by -15.05% Decreased by -58.15% |
| Dec 31, 24 | 26.31 M Increased by +48.70% | -1.54 M Decreased by -548.66% | Decreased by -5.85% Decreased by -336.21% |
| Sep 30, 24 | 21.67 M Increased by +35.24% | -2.86 M Decreased by -169.51% | Decreased by -13.19% Decreased by -99.29% |
| Jun 30, 24 | 20.16 M Increased by +27.97% | -3.50 M Decreased by -91.71% | Decreased by -17.38% Decreased by -49.82% |
| Mar 31, 24 | 18.54 M Increased by +19.42% | -1.76 M Decreased by -17.29% | Decreased by -9.52% Increased by +1.78% |
| Dec 31, 23 | 17.69 M Increased by +15.50% | -237.19 K Increased by +97.97% | Decreased by -1.34% Increased by +98.25% |
| Sep 30, 23 | 16.02 M Increased by +22.85% | -1.06 M Increased by +30.66% | Decreased by -6.62% Increased by +43.56% |
| Jun 30, 23 | 15.75 M Increased by +62.89% | -1.83 M Increased by +43.68% | Decreased by -11.60% Increased by +65.43% |